Drivers of Successful Reimbursement Decisions of Orphan Drugs in SpainOmakase2022-11-24T18:55:07+00:00November 24th, 2022|
Analysis of the negative reimbursement of Orphan Drugs in the Spanish National Health System (2019-2022)Omakase2022-11-24T18:55:21+00:00November 24th, 2022|
Do you want to know factors influencing Orphan PnR in Spain?Omakase2022-11-24T18:55:34+00:00November 24th, 2022|
Efficiency of Third-generation antiseizure medications in Spain for Drug-resistant epilepsy: A Cost-per-Number Needed to Treat AnalysisOmakase2022-11-24T18:56:03+00:00November 24th, 2022|
“Value Contribution of Olipudase Alfa therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)”Omakase2022-11-24T18:56:21+00:00November 24th, 2022|
Posters presented by Omakase Consulting at the ISPOR 20th Annual European Congress are available for downloading Posters presented by Omakase Consulting at the ISPOR 20th Annual European Congress are available for downloading Posters presented by Omakase Consulting at the ISPOR 20th Annual European Congress are available for downloadingOmakase2020-09-08T15:13:49+00:00November 9th, 2017|
